Loading...
•
Jun 30, 2024
Zai Lab Q2 2024 Earnings Report
Achieved impressive commercial growth, maintained financial discipline, and made significant strides across product portfolio.
Key Takeaways
Zai Lab reported a strong second quarter with net product revenue of $100.1 million, representing 45% year-over-year growth. The company saw significant contributions from VYVGART, ZEJULA, and NUZYRA, and is on track to achieve profitability by the end of 2025.
Net product revenue of $100.1 million for the second quarter of 2024, representing 45% y-o-y growth.
VYVGART® (efgartigimod alfa injection) sales of $23.2 million for the second quarter of 2024; raising full-year VYVGART revenue guidance to exceed $80.0 million.
Three product approvals in China including XACDURO® for HABP/VABP, efgartigimod SC for gMG, and AUGTYRO™ for ROS1+ NSCLC.
Strong balance sheet with a cash position of $730.0 million as of June 30, 2024.
Revenue by Segment
Forward Guidance
Zai Lab did not include forward guidance in this report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...